Search Results
Aug 10, 2026, 02:36 ET Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma
Aug. 10, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and Innate Pharma SA (Euronext Paris: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase
More news about: Swedish Orphan Biovitrum AB
Aug 10, 2026, 02:32 ET Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma
Aug. 10, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and Innate Pharma SA (Euronext Paris: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase
More news about: Swedish Orphan Biovitrum AB
Jun 02, 2026, 09:02 ET A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company
differently the market values programs at various stages — and how much capital is chasing the same fundamental idea.Innate Pharma S.A. (NASDAQ: IPHA) is the closest mechanistic comparison. Its proprietary ANKET® platform builds multi-specific NK cell engagers — the same broad class of molecule as
More news about: USA News Group
May 18, 2026, 14:22 ET B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic
the antigen that supports the broader investment thesis around B7-H3-targeted programs at every scale.Innate Pharma S.A. (NASDAQ: IPHA) has long been one of the more prominent publicly listed pure-play NK cell engager companies, with multispecific approaches that hit triggering receptors
More news about: USA News Group